908 Devices Kicks Off 2026 with Strong Q1, Acquires NIRLAB

908 Devices kicked off 2026 with a strong first quarter, reporting revenue of $13.4 million, a 14% increase from last year. U.S. state and local sales drove half of this growth, marking the third consecutive quarter of beating internal targets. The company announced acquiring NIRLAB AG, a Swiss firm with near-infrared tech for quick field drug detection, for $15 million upfront. This deal expands their narcotics lineup and is expected to generate $2.5 million in revenue this year, scaling to over $5 million in 2027. Investors and analysts praised the acquisition for its fit with end-to-end workflows amid rising drug threats. Financials improved with gross margins rising to 51% and adjusted EBITDA loss shrinking by 45%. Full-year guidance was raised to $67-$70 million, with handheld sales leading at $62-$64 million. Momentum is building as the company scales platforms, boosts recurring revenue, and chases global handheld dominance. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2b33a6de954dcec9